ZEAL

No price yet

Announcements

Nothing here yet

Daily updates

Zealand Pharma shares dipped after its Boehringer Ingelheim-partnered survodutide reported underwhelming weight-loss results in a second Phase 3 trial. SYNCHRONIZE-2 showed up to 13.1% weight loss at 76 weeks by efficacy estimand in Boehringer's release, while NEJM reported up to 9.8% with the highest 6 mg dose.Oct 1, 2026

FDA designations

Nothing here yet

News

Zealand Pharma reports positive topline results from the multiple-ascending-dose portion of the Phase 1 trial of its Kv1.3 ion channel blocker ZP9830Oct 19, 2026
Zealand Pharma reports mixed Phase 2 results for petrelintide, marking the second mixed outcome for its weight-loss pipeline in a weekOct 8, 2026
Zealand Pharma shares fell after partnered survodutide delivered weaker-than-expected weight loss results in a second Phase 3 trialOct 1, 2026
Zealand Pharma reports that Boehringer Ingelheim's survodutide delivered up to 13.1% weight loss in a new Phase 3 trial, with significant improvements in glycemic control in people with obesity and type 2 diabetesOct 1, 2026